ReviewBrain sciences2022
Mixed Depression: A Mini-Review to Guide Clinical Practice and Future Research Developments.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association of FKBP5 gene polymorphism with genetic susceptibility to depression and response to antidepressant treatment- a systematic review.BMC psychiatry · 2024Pooled it
- Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis.Frontiers in psychiatry · 2024Pooled it
- A preliminary cross-sectional study of bipolarity and primary pharmacotherapy in long-term stable patients with major depressive disorder.International journal of bipolar disorders · 2026Article
- Social Rhythms, Depressive Symptoms, and Quality of Life: An Unbreakable Bond in an Older Adult Sample.International journal of environmental research and public health · 2026Observational
- Inflammatory, clinical and sociodemographic factors associated with depressive disorder during pregnancy in Brazilian women.Scientific reports · 2026Article
- Altered core depressive symptom balance in post-COVID fatigue: reduced depressed mood in an exploratory matched historical-control study.Frontiers in psychiatry · 2026Article
- Expert Guidelines on the Use of Cariprazine in Bipolar I Disorder: Consensus from Southeast Asia.Healthcare (Basel, Switzerland) · 2025Article
- Editorial: Case reports in Schizophrenia and psychotic disorders: 2023.Frontiers in psychiatry · 2025Article
- Editorial: Neuroimaging in psychiatry 2023: mood disorders.Frontiers in psychiatry · 2025Article
- Prevalence of mixed features in patients with first-episode depression: An exploratory multicentric study.Indian journal of psychiatry · 2023Article
- Genetic and epigenetic factors associated with depression: An updated overview.Saudi journal of biological sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The debate on mixed states (MS) has been intense for decades. However, several points remain controversial from a nosographic, diagnostic, and therapeutic point of view. The different perspectives that have emerged over the years have turned into a large, but heterogeneous, literature body. The present review aims to summarize the evidence on MS, with a particular focus on mixed depression (MxD), in order to provide a guide for clinicians and encourage the development of future research on the topic. First, we review the history of MS, focusing on their different interpretations and categorizations over the centuries. In this section, we also report alternative models to traditional nosography. Second, we describe the main clinical features of MxD and list the most reliable assessment tools. Finally, we summarize the recommendations provided by the main international guidelines for the treatment of MxD. Our review highlights that the different conceptualizations of MS and MxD, the variability of clinical pictures, and the heterogeneous response to pharmacological treatment make MxD a real challenge for clinicians. Further studies are needed to better characterize the phenotypes of patients with MxD to help clinicians in the management of this delicate condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.